Evidence map›Paper›PMID 25827529›Full record

ArticleVirology2015

Mucosal vaccination by adenoviruses displaying reovirus sigma 1.

Eric A Weaver, Zenaido T Camacho, Matthew L Hillestad, Catherine M Crosby, Mallory A Turner, Adam J Guenzel, Hind J Fadel, George T Mercier, Michael A Barry

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Eric A WeaverDepartment of Internal Medicine, Division of Infectious Diseases, Translational Immunovirology and Biodefense Program, Mayo Clinic, Rochester, MN 55902, USA.
Zenaido T CamachoDepartment of Cell Biology, Department of Natural Sciences, Western New Mexico University, Silver City, NM 88062, USA.
Matthew L HillestadNephrology Training Program, Mayo Clinic, Rochester, MN 55902, USA.
Catherine M CrosbyVirology and Gene Therapy Graduate Program, Mayo Clinic, Rochester, MN 55902, USA.
Mallory A TurnerVirology and Gene Therapy Graduate Program, Mayo Clinic, Rochester, MN 55902, USA.
Adam J GuenzelVirology and Gene Therapy Graduate Program, Mayo Clinic, Rochester, MN 55902, USA.
Hind J FadelVirology and Gene Therapy Graduate Program, Mayo Clinic, Rochester, MN 55902, USA.
George T MercierDepartment of Physics, University of Houston, Houston, TX 77004, USA.
Michael A BarryDepartment of Internal Medicine, Division of Infectious Diseases, Translational Immunovirology and Biodefense Program, Mayo Clinic, Rochester, MN 55902, USA; Department of Immunology and Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55902, USA. Electronic address: mab@mayo.edu.
Mayo Clinic in Florida · USMayo Clinic · USUniversity of Houston · USWestern New Mexico University · US

Funding

Immunoevasive Mucosal Vaccines Against HIV-1R01AI096967 · NIAID · MAYO CLINIC ROCHESTER · PI BARRY, MICHAEL A · 2012 to 2016
$3.0M
Foundation Immunogens for Influenza VaccinesR01AI097241 · NIAID · UNIVERSITY OF NEBRASKA LINCOLN · PI WEAVER, ERIC A · 2012 to 2015
$1.6M
NIAID NIH HHS R01 AI096967NIAID NIH HHS R01AI096967NIAID NIH HHS R01 AI097241
6 · The paper itself

Abstract

We developed adenovirus serotype 5 (Ad5) vectors displaying the sigma 1 protein from reovirus as mucosal vaccines. Ad5-sigma retargets to JAM-1 and sialic acid, but has 40-fold reduced gene delivery when compared to Ad5. While weaker at transduction, Ad5-sigma generates stronger T cell responses than Ad5 when used for mucosal immunization. In this work, new Ad5-fiber-sigma vectors were generated by varying the number of fiber β-spiral shaft repeats (R) between the fiber tail and sigma. Increasing chimera length led to decreasing insertion of these proteinsAd5 virions. Ad-R3 and R14 vectors effectively targeted JAM-1 in vitro while R20 did not. When wereused to immunize mice by the intranasal route, Ad5-R3-sigma produced higher serum and vaginal antibody responses than Ad5. These data suggest optimized Ad-sigma vectors may be useful vectors for mucosal vaccination.

Indexed as

Cell Surface Display TechniquesAdenoviridaeAdministration, IntranasalAnimalsAntibodies, ViralCapsid ProteinsFemaleGenetic VectorsMice, Inbred BALB CRecombinant ProteinsReoviridaeSerumVaccinationVaccines, SyntheticVaginaViral VaccinesAntibodies, ViralCapsid ProteinsRecombinant Proteinssigma 1 protein, reovirusVaccines, SyntheticViral VaccinesAdenovirusImmunizationMucosalReovirusSigma 1

Identifiers

PMID25827529
PMCPMC4461457
OpenAlexW2088132242

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.